In a statement signed by its Director-General, Prof. Mojisola Adeyeye, NAFDAC said the medical supplies were intended to help address gaps in HIV/AIDS treatment following changes associated with the exit of the United States Agency for International Development (USAID).
The agency stressed that cooperation with foreign regulators would not remove its statutory responsibility to protect Nigerians from unsafe, substandard or ineffective medical products.
NAFDAC explained that the agreement draws on its existing regulatory-reliance framework with the United States Food and Drug Administration (FDA). Under this arrangement, eligible products manufactured in the United States and approved by the US regulator may benefit from an expedited review process, subject to applicable Nigerian requirements.
However, products not manufactured in the United States will undergo NAFDAC’s assessment of quality, safety and efficacy, according to the agency. It also retains the authority to review applications, inspect products and manufacturing facilities, conduct risk-based testing and carry out post-market surveillance where necessary.
The regulator cited its experience during the COVID-19 pandemic, when it said vaccines administered in Nigeria were tested at its Vaccine, Biologics and Medical Devices Laboratory in Yaba, Lagos, despite having received World Health Organization safety assessments.
NAFDAC also stated that antiretroviral, tuberculosis and malaria medicines supplied through the Global Fund were subjected to annual testing as part of its quality assurance activities.
On distribution monitoring, the agency said it had previously used the GS1 technology-based Track and Trace system to monitor COVID-19 vaccines across Nigeria. Records from the process were maintained in its Traceability Information System (TIS), which has since been extended to other vaccines.
The system is also being used to monitor the supply chains for narcotics and maternal, newborn and child health commodities. NAFDAC said it would apply the same tracking framework to medical products supplied under the USG-GoN agreement.
The technology is intended to improve visibility of product movement through the supply chain and strengthen accountability in the distribution of medicines and vaccines.
NAFDAC maintained that the arrangement would not exempt medical supplies from applicable Nigerian regulatory requirements. It said protecting public health and ensuring the quality, safety and efficacy of medicines remain central to its mandate.
The announcement comes as Nigeria and the United States pursue a broader health cooperation framework covering infectious disease control, health security and access to essential medical commodities. The effectiveness of the supply programme will depend not only on the availability of products but also on appropriate regulatory checks, transparent distribution and reliable monitoring.
Reporting by TalkNaija Media
Reader Comments (0)
No comments yet. Be the first to share your perspective on this report.